Abstract

Mahmoud Mahyoob Alburyhi*, Abdalwali Ahmed Saif and Maged Alwan Noman

ABSTRACT

Multiparticulate drug delivery systems are important because they are simple to build and can control drug release in various ways, such as rate control, site control, or both. In the present study that the Lornoxicam was chosen to be the active pharmaceutical ingredient (API) in microsponge gel preformulation. Drug-entrapped microsponge can be used to make a variety of formulations, including tablets, gels, capsules, powders, lotions, and creams. This microsponge drug delivery technique provides enhanced drug entrapment and stability, allowing for greater formulation flexibility and a significant reduction in unwanted side effects. Lornoxicam (chlortenoxicam), a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties, is available in oral and parenteral formulations. It differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. It is a strong analgesic and anti-inflammatory NSAID as compared to other NSAIDs. A total of four microsponge gel formulations of Lornoxicam with excipients like; Eudragit, Polyvinyl alcohol (PVA) in different ratios were prepared with a view to increase its effect by decreasing the time required for the drug to be released. Preformulation, formulation and evaluation of Lornoxicam to avoid problems associated with conventional delivery system such as limited permeation, low dissolution and bioavailability. Preformulation studies parameters were evaluated. It was concluded that the drug Lornoxicam was found to be compatible with various excipients which were selected for the formulation development of the Lornoxicam microsponge gel DDS. Formulation scientist from his experience and knowledge have to significantly in the preformulation study stage and is an important factor in the ADDS (Advanced Drug Delivery Systems) product development process.